XML 17 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
Note 1 - Organization and Nature of Business
3 Months Ended
Mar. 31, 2017
Notes to Financial Statements  
Nature of Operations [Text Block]
NOTE
1
ORGANIZATION AND NATURE OF BUSINESS
 
Company Background
 
Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”), a Delaware corporation with
one
subsidiary named Protagenic Therapeutics Canada
(2006)
Inc., is a corporation formed in
2006
under the laws of the Province of Ontario, Canada.
 
The Company was most recently known as Atrinsic, Inc., a company that was once a reporting company under the Securities Act, but that, in
2012
and
2013,
reorganized under Chapter
11
of the United States Bankruptcy Code and emerged from bankruptcy. On
February
12,
2016,
the Company acquired Protagenic Therapeutics, Inc. (“Prior Protagenic”) through a reverse merger. On
June
17,
2016,
Protagenic Therapeutics, Inc. (the then wholly-owned subsidiary of Atrinsic, Inc.) was merged with and into Atrinsic, Inc. Atrinsic, Inc. was the surviving corporation in this merger and changed its name from Atrinsic, Inc. to Protagenic Therapeutics, Inc.
 
The Company is a biotechnology company focused on the discovery, research and development of pre-clinical studies for developing novel, naturally occurring, human neuropeptide-based, brain- active therapeutics for treatment of depression, mood, anxiety and other neurodegenerative disorders. The Company is also interested in acquiring exclusive intellectual property rights for peptide-based therapeutics for the treatment of neurological and mood disorders.